Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

Completed 87 enrolled Massachusetts General Hospital Cambridge Health Alliance · collab MaineHealth · collab National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).

Timeline

Start: 2021-08-23
Primary completion: 2025-05-01
Completion: 2025-10-31

Outcome

Missed primary endpoint

registry analysis (superiority test); Cannabis (CB) vs Waitlist (WL); p = 0.45; Median Difference (Final Values) 15.4 (95% CI -24.4 to 55.3) NCT04827992 ↗

registry analysis (superiority test); Cannabis (CB) vs Waitlist (WL); p = 0.85; Median Difference (Net) 0.05 (95% CI -0.46 to 0.57) NCT04827992 ↗

Publications

Background Jashinski J, Grossman E, Quaye A, Cather C, Potter K, Schoenfeld DA, Evins AE, Gilman JM. Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol. BMJ Open. 2022 Jun 9;12(6):e064457. doi: 10.1136/bmjopen-2022-064457.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabis	Traditional medicine (herbal / TCM)	—	—